Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ»ç¼±Ä¡·á·Î ÀÎÇÑ ÅëÁõ ¹× ¾Ï¼ºÅëÁõ¿¡ ´ëÇÑ µà·ÎÁ¦½ÄÀÇ È¿°ú: ´Ù±â°ü¿¬±¸ Effectiveness of Fentanyl Transdermal Patch (Fentanyl-TTS, Durogegic¨Þ) for Radiotherapy Induced Pain and Cancer Pain: Multi-center Trial

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 4È£ p.263 ~ 271
½Å¼º¼ö, ½ÅÇö¼ö, Çã½ÂÀç, ÃÖÀº°æ, ±èÁ¾ÈÆ, ¾È½Âµµ, ÀÌ»ó¿í, ±è¿¬½Ç, À̱ÔÂù, ÀÌâ°É, ³ëÁرÔ, Àü¹Ì¼±, ¿À¿µÅÃ, ±è¿Á¹è, ±èÁøÈñ, ±èö¿ë, ¾ç´ë½Ä, ¹Ú¿ìÀ±, ±èº¸°æ, Á¶Èï·¡, ¾È±âÁ¤, ÀÌÁ¾¿µ, À±¼±¹Î, ¾È¿ëÂù, ÀÓµµÈÆ, ¹Ú¿ø, °­±â¹®, ¿ìÈ«±Õ, À强¼ø, ±èÀº¼®, ±è¿ëÈ£, ³ªº´½Ä, Á¤¿õ±â, ³²ÅñÙ, ¾È¼ºÀÚ, ¼Û¹ÌÈñ, À±»ó¸ð, °èö½Â, ¿¹Áö¿ø, ¹Ú¼®¿ø, ±è¼±¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
½Å¼º¼ö ( Shin Seong-Soo ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø

½ÅÇö¼ö ( Shin Hyun-Soo ) 
Æ÷õÁß¹®ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇаú
Çã½ÂÀç ( Huh Seung-Jae ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÃÖÀº°æ ( Choi Eun-Kyung ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø
±èÁ¾ÈÆ ( Kim Jong-Hoon ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø
¾È½Âµµ ( Ahn Seung-Do ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø
ÀÌ»ó¿í ( Lee Sang-wook ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø
±è¿¬½Ç ( Kim Yeon-Sil ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ °­³²¼º¸ðº´¿ø
À̱ÔÂù ( Lee Kyu-Chan ) 
°¡Ãµ´ëÇб³º´¿ø
ÀÌâ°É ( Lee Chang-Geol ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ½ÅÃ̼¼ºê¶õ½ºº´¿ø
³ëÁرԠ( Loh John-JK ) 
ÀÎÇÏ´ëÇб³º´¿ø
Àü¹Ì¼± ( Chun Mi-Son ) 
¾ÆÁÖ´ëÇб³º´¿ø
¿À¿µÅà( Oh Young-Teak ) 
¾ÆÁÖ´ëÇб³º´¿ø
±è¿Á¹è ( Kim Ok-Bae ) 
°è¸í´ëÇб³ µ¿»êº´¿ø
±èÁøÈñ ( Kim Jin-Hee ) 
°è¸í´ëÇб³ µ¿»êº´¿ø
±èö¿ë ( Kim Chul-Yong ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¾È¾Ïº´¿ø
¾ç´ë½Ä ( Yang Dae-Sik ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¾È¾Ïº´¿ø
¹Ú¿ìÀ± ( Park Woo-Yoon ) 
ÃæºÏ´ëÇб³º´¿ø ¼Ò¾Æ°úÇб³½Ç
±èº¸°æ ( Kim Bo-Kyoung ) 
´Ü±¹´ëÇб³º´¿ø
Á¶Èï·¡ ( Cho Heung-Lae ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø
¾È±âÁ¤ ( Ahn Ki-Jung ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø
ÀÌÁ¾¿µ ( Lee Jong-Young ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿øÁֱ⵶º´¿ø
À±¼±¹Î ( Youn Seon-Min ) 
À»Áö´ëÇб³º´¿ø
¾È¿ëÂù ( Ahn Yong-Chan ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼­¿ïº´¿ø ´ëÀå¼¾ÅÍ ¿Ü°úÇб³½Ç
ÀÓµµÈÆ ( Lim Do-Hoon ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼­¿ïº´¿ø ´ëÀå¼¾ÅÍ ¿Ü°úÇб³½Ç
¹Ú¿ø ( Park Won ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼­¿ïº´¿ø ´ëÀå¼¾ÅÍ ¿Ü°úÇб³½Ç
°­±â¹® ( Kang Ki-Moon ) 
°æ»ó´ëÇб³º´¿ø
¿ìÈ«±Õ ( Wu Hong-Gyun ) 
¼­¿ï´ëÇб³º´¿ø
À强¼ø ( Jang Seong-Soon ) 
´ëÀü¼º¸ðº´¿ø
±èÀº¼® ( Kim Eun-Seog ) 
¼øõÇâ´ëÇб³º´¿ø
±è¿ëÈ£ ( Kim Yong-Ho ) 
¼øõÇâ´ëÇб³º´¿ø
³ªº´½Ä ( Nah-Byung-Sik ) 
Àü³²´ëÇб³º´¿ø
Á¤¿õ±â ( Chung Woong-Ki ) 
Àü³²´ëÇб³º´¿ø
³²Åñ٠( Nam Taek-Keun ) 
Àü³²´ëÇб³º´¿ø
¾È¼ºÀÚ ( Ahn Sung-Ja ) 
Àü³²´ëÇб³º´¿ø
¼Û¹ÌÈñ ( Song MI-Hee ) 
±¹¸³ÀÇ·á¿ø
À±»ó¸ð ( Yun Sang-Mo ) 
¿µ³²´ëÇб³º´¿ø
°èö½Â ( Kay Chul-Seung ) 
ÇѶ󺴿ø
¿¹Áö¿ø ( Yei Ji-won ) 
´ë±¸°¡Å縯ÀÇ°ú´ëÇб³º´¿ø
¹Ú¼®¿ø ( Park Suk-Won ) 
Áß¾Ó´ëÇб³º´¿ø
±è¼±¿ì ( Kim Seon-Woo ) 
»ï¼º»ý¸í¿¬±¸¼Ò

Abstract

¸ñ Àû: ¹æ»ç¼±Ä¡·á·Î ÀÎÇØ ¹ß»ýÇÏ´Â Á¡¸·¿°, ½Äµµ¿° µîÀÇ ÅëÁõ°ú ¾Ï¼º ÅëÁõÀ» °¡Áø ȯÀÚ¿¡ ´ëÇÑ µà·ÎÁ¦½ÄÀÇ ÅëÁõ
¿ÏÈ­ ¹× ÀÏ»ó»ýÈ° °³¼± È¿°ú¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: ´Ù±â°ü ÀüÇâÀû 4»ó ÀÓ»ó½ÃÇèÀ¸·Î ¹æ»ç¼±Ä¡·á·Î ÀÎÇÑ ÅëÁõÀ» È£¼ÒÇϰųª(A±º) ¾Ï¼ºÅëÁõÀ¸·Î ¹æ»ç¼±
Ä¡·á¸¦ ½ÃÇà ¹Þ°í Àִ ȯÀÚ(B±º) Áß¿¡ ÁøÅëÁ¦¸¦ º¹¿ë ÁßÀÓ¿¡µµ ¼ýÀÚµî±ÞÆò°¡(Numeric rating scale, NRS)°¡ 4 ÀÌ»ó
À̰ųª ÁøÅëÁ¦ º¹¿ë ¾øÀÌ NRS°¡ 6 ÀÌ»óÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î µà·ÎÁ¦½Ä 25 ug/hrÀ» ó¹æÇÑ ÈÄ¿¡ 1ÁÖÀÏ°ú 2ÁÖÀÏ ÈÄ¿¡
ÅëÁõȽ¼ö¿Í °­µµº¯È­, ÅëÁõÀÌ ÀÏ»ó»ýÈ°¿¡ ¹ÌÄ¡´Â ¿µÇâÆò°¡, ÇÇÇèÀÚ¿Í ÀÓ»óÀÇ ¸¸Á·µµ Æò°¡, ±×¸®°í ÀÌ»ó¹ÝÀÀ Æò°¡¸¦
½ÃÇàÇÏ¿´´Ù.

°á °ú: 2005³â 3¿ù 28ÀϺÎÅÍ 6¿ù 15ÀϱîÁö 26°³ ±â°ü¿¡¼­ ÃÑ 312¸íÀÇ ÇÇÇèÀÚ¸¦ µî·ÏÇÏ¿´°í ±× Áß 249¸íÀÌ ÀÓ»ó½Ã
ÇèÀ» ¿Ï·áÇÏ¿´´Âµ¥ A±ºÀº 185¸í, B±ºÀº 64¸íÀÌ¿´´Ù. Æò±Õ ¿¬·ÉÀº 60¼¼¿´°í, ³²ÀÚ°¡ 189¸í, ¿©ÀÚ°¡ 60¸íÀÌ¿´´Ù. 2ÁÖ
ÈÄ °¡Àå ½ÉÇÑ ÅëÁõÀÇ °­µµ º¯È­¸¦ º¸¸é A±º¿¡¼­ 6.9¿¡¼­ 3.9·Î B±º¿¡¼­´Â 7.1¿¡¼­ 3.9·Î Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô
(p=0.003) °¨¼ÒÇÏ¿´°í ÀÏ»ó»ýÈ°ÀÇ ¹ÌÄ¡´Â ¿µÇâÀ» º¸±â À§ÇÑ ¼ö¸é¹æÇØ Á¤µµ¿Í ÀÏ»óÀûÀÎ ÀÏÀÇ ÀúÇÏ ±×¸®°í »îÀÇ ÁúÀÇ
ÀúÇÏ´Â Åõ¿© 2ÁÖ ÈÄ¿¡ ¸ðµÎ È£ÀüµÇ¾ú´Ù. ¿¬ÇÏÅëÁõÀÇ º¯È­´Â A±º¿¡¼­¸¸ À¯ÀÇÇÏ°Ô Åõ¿© ÈÄ È£ÀüµÇ¾úÀ¸¸ç ÇÇÇèÀÚÀÇ
¸¸Á·µµ´Â ¸Å¿ì ¸¸Á·ÀÌ A¿¡¼­ 47%, B±º¿¡¼­ 41%·Î ÁÁ¾Ò°í ¸¸Á· ÀÌÀ¯´Â ÁøÅëÈ¿°ú ¿ì¼ö, Àü¹ÝÀû ¸¸Á·, Æí¸®¼º ¼øÀÌ
¾ú´Ù. ÀÓ»óÀÇ ¸¸Á·µµ´Â ¸Å¿ì¸¸Á·ÀÌ 50% Á¤µµ·Î ÁÁ¾Ò´Ù. ÀÌ»ó¹ÝÀÀÀº A±º¿¡¼­ 40% B±º¿¡¼­ 34%·Î ÃÑ 38%¿¡¼­ ³ª
Ÿ³µ°í ¿À½ÉÀÌ 30%·Î °¡Àå ¸¹¾Ò°í ¼Ò¾çÁõ 16%, ¾îÁö·¯¿ò 14%, º¯ºñ 10% ¼øÀ̾ú´Ù. Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀº ¾ø¾ú´Ù.

°á ·Ð: µà·ÎÁ¦½ÄÀÇ ÅëÁõ¿ÏÈ­ È¿°ú ÀÏ»ó»ýÈ° °³¼±È¿°ú´Â ¿ì¼öÇÏ¿´°í ÇÇÇèÀÚ¿Í ÀÓ»óÀÇÀÇ ¸¸Á·µµµµ ÁÁ¾Ò°í Áß´ëÇÑ ÀÌ
»ó¹ÝÀÀµµ ¾ø¾ú´Ù.

Purpose: To evaluate the effectiveness and safety of fentanyl-TTS in the management of radiotherapy induced
acute pain and cancer pain treated with radiotherapy.

Materials and Methods: Our study was open labelled prospective phase IV multi-center study. the study
population included patients with more 4 numeric rating scale(NRS) score pain although managed with other
analgesics or more than 6 NRS score pain without analgesics. Patients divided into two groups; patients with
radiotherapy induced pain (Group A) and patients with cancer pain treated with radiotherapy (Group B). All
patients received 25 ug/hr of fentanyl transdermal patch. Primary end point was pain relief; second end points
were change in patient quality of life, a degree of satisfaction for patients and clinician, side effects.

Results: Between March 2005 and June 2005, 312 patients from 26 participating institutes were registered, but
249 patients completed this study. Total number of patients in each group was 185 in Group A, 64 in Group
B. Mean age was 60 years and male to female ratio was 76:24. Severe pain NRS score at 2 weeks after the
application of fentanyl was decreased from 7.03 to 4.01, p=0.003. There was a significant improvement in
insomnia, social functioning, and quality of life. A degree of satisfaction for patients and clinician was very high.
The most common reasons of patients¡¯ satisfactions was good pain control. Ninety six patients reported side
effect. Nausea was the most common side effect. There was no serious side effect.

Conclusion: Fentanyl-TTS was effective in both relieving pain with good tolerability and improving the quality
of life for patients with radiotherapy induced acute pain and cancer pain treated with radiotherapy. The
satisfaction of the patients and doctors was good. There was no major side effect.

Å°¿öµå

¾Ï¼ºÅëÁõ;¹æ»ç¼±Ä¡·á·Î ÀÎÇÑ ÅëÁõ;µà·ÎÁ¦½Ä
Cancer pain;Radiotherapy induced pain;Fentanyl Transdermal Patch

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS